Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05053607|
Recruitment Status : Recruiting
First Posted : September 22, 2021
Last Update Posted : May 12, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable activity data will be collected. Outcomes include treatment experience, quality of life, financial toxicity, treatment adherence, symptom burden and health self-efficacy. These will be captured by patient reported outcome measures including the Patient's Qualitative Assessment of Treatment- Real World (PQAT-RW), Patient Global Impression of Change/Severity (PGIC/S), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20), and the European QoL-5 Dimensions (EQ5D), Cancer Behavior Inventory-Brief Form (CBI-B), Center for Adherence Support Evaluation (CASE) Medication Adherence Index, Comprehensive Score for Financial Toxicity (COST) Instrument.
Clinical data, including treatment history, healthcare utilization, and co-morbidities, as well as demographic data will be collected via the electronic health record from each clinical site. This data will be complemented by qualitative data from a selected cohort of study participants with a focus on treatment experience ranging from infusion burden, toxicity management, to overall quality of life. Evaluation of this data in combination will be used to better understand the treatment experience of individuals on standard of care isatuximab-irfc specifically, and with relapsed or refractory multiple myeloma generally, contributing to an existing gap in the literature regarding patient reported outcomes from diverse data sources. Outcomes will be analyzed with attention to the relationship between social determinants of health, including race, ethnicity, and geographic location, and treatment experience as reflected in both the qualitative and quantitative data.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma Refractory Multiple Myeloma||Behavioral: Digital Health Coaching Program Device: Fitbit||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||A single cohort of 50 individuals with relapsed/refractory multiple myeloma will be enrolled in the study, all of which will be enrolled in a digital health coaching program and receive a Fitbit device for activity tracking. Individuals from both study sites will be enrolled to this single cohort.|
|Masking:||None (Open Label)|
|Official Title:||Clinical and Patient Reported Outcomes for Individuals With Relapsed/Refractory Multiple Myeloma Treated With Isatuximab: Real-World Insights From Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching|
|Actual Study Start Date :||June 17, 2022|
|Estimated Primary Completion Date :||August 2023|
|Estimated Study Completion Date :||December 2023|
1. Single Arm Cohort Receiving Digital Health Coaching
All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data.
Participants have the option to participate in a one time interview about their treatment experience.
Behavioral: Digital Health Coaching Program
consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
- Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW) [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A 6-item survey assessing experience of a drug during clinical trial. The instrument consists of 3-free text and 3 scaled responses assessing the perceived benefits and disadvantages of received treatment and willingness to continue on drug after the study.
- Qualitative Interview [ Time Frame: Within the last month of study participation ]A one time interview will be conducted to learn more about the experience of individuals related to their diagnosis, treatment, symptoms, side effects and overall care experience.
- Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A 30-item measure of quality of life across 5 domains, including physical, emotional, social, role and cognitive), 8 symptoms, and items assessing global health and financial toxicity. Recall over the past week is scored primarily on a 4-point scale ranging from "not at all" to "very much". The instrument may be administered either on paper or electronically.
- Change in Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20) [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A 20-item measure of quality of life among individuals with multiple myeloma. It assesses a series of symptoms on a 4-point Likert scale ranging from 1 (Not at All) to 4 (Very Much).
- Change in European QoL-5 Dimensions (EQ5D) [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A measure of quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
- Change in Cancer Behavior Inventory-Brief Form (CBI-B) [ Time Frame: Change in baseline perception of treatment experience at 3 months ]This 12-item instrument measures self-efficacy in coping with cancer across 7 domains. These include: Seeking and Understanding Medical Information, Emotion Regulation, Coping with Treatment Related Side Effects, Accepting Cancer/ Maintaining a Positive Attitude, Seeking Social Support, and Using Spiritual Coping. The instrument utilizes a 9-point response scale ranging from 1 "Not at all confident" to 9 "Confident".
- Change in Patient Global Impression of Severity (PGIS) Scale [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A 1-item measure of severity of relapsed/refractory multiple myeloma symptoms since the last visit, which is scored a on a 5-response scale ranging from "none" to "very severe".
- Change in Patient Global Impression of Change (PGIC) Scale [ Time Frame: Change in baseline perception of treatment experience at 3 months ]A 1-item measure of patient perception of change in relapsed/refractory multiple myeloma symptoms since starting a study. Responses are scored on a 7-point scale, ranging from "very much worse" to "very much better".
- Change in Center for Adherence Support Evaluation (CASE) Medication Adherence Index [ Time Frame: Change in baseline perception of treatment experience at 3 months ]The Center for Adherence Support Evaluation (CASE) is a three-item questionnaire used to measure antiretroviral therapy adherence. This questionnaire was developed through the Special Projects of National Significance (SPNS) initiative called Assessing Existing Efforts to Increase Adherence to Medication. Patients take less than 5 minutes to answer the three unique questions, asking about their difficulty taking medications on time, average days per week with one dose missed, and the last time they missed a dose.
- Change in Comprehensive Score for Financial Toxicity (COST) Instrument [ Time Frame: Change in baseline perception of treatment experience at 3 months ]The Comprehensive Score for Financial Toxicity (COST) is an 11-item instrument used to measure the financial toxicity of cancer treatment, which has been demonstrated to be highly correlated with HRQoL (de Souza et al., 2017). This instrument was validated among individuals with advanced cancer and demonstrated high internal consistency (Cronbach's α >.90) and highly correlated to HRQol (p=.05). The instrument consists of 11 items, utilizing a five-point ordinal scale ranging from (0- Not at all) to (4- Very much).
- Physical Activity [ Time Frame: From date of enrollment up to 3 months ]Physical activity, including step count and minutes of physical activity will be collected via Fitbits provided to study participants
- Health Care Utilization [ Time Frame: From date of enrollment up to 3 months ]ER visits and unplanned hospitalizations
- Digital Engagement [ Time Frame: From date of enrollment up to 3 months ]Frequency, types and duration of engagement with the digital health coaching platform
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age 18 or older
- Diagnosis of relapsed/refractory multiple myeloma corresponding to the Food and Drug Administration (FDA) package insert for isatuximab-irfc (Sarclisa®).
- Confirmed or planned treatment with intravenous isatuximab-irfc for relapsed/refractory multiple myeloma as standard-of-care therapy. Concurrent therapy with other agents (e.g., pomalidomide) is allowed.
- Access to and willingness to use a smartphone or other device through which they can send and receive text messages, emails and/or access a mobile application.
- Willingness to wear and have data collected by a Fitbit
- Ability to engage in physical activity as evidenced by an Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 2
- Individuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment)
- Individuals for whom there is documentation of inability to provide consent in the medical record.
- Individuals receiving isatuximab-irfc subcutaneously
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05053607
|Contact: Kelly J Brassil, PhDemail@example.com|
|Contact: Austin Barr, MPHfirstname.lastname@example.org|
|United States, Texas|
|The University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77074|
|Contact: Jasper Olsem MYE_PackHealth0309@mdanderson.org|
|Principal Investigator: Elisabet Manasanch, MD|
|United States, Washington|
|University of Washington||Recruiting|
|Seattle, Washington, United States, 98109|
|Contact: Trenton Grossfeld, BS 206-606-1774 email@example.com|
|Principal Investigator: Rahul Banerjee, MD|
|Principal Investigator:||Elisabet Manasanch, MD||The University of Texas MD Anderson Cancer Center|
|Principal Investigator:||Rahul Banerjee, MD||University of Washington|
|Responsible Party:||Pack Health|
|Other Study ID Numbers:||
|First Posted:||September 22, 2021 Key Record Dates|
|Last Update Posted:||May 12, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
wearable electronic devices
patient reported outcome measures
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases